Elixiron Immunotherapeutics Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elixiron Immunotherapeutics Inc
Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2
New VC deals include a $60m series C-1 round for DiCE Molecules a day before it filed paperwork to support a $100m IPO and a $100m financing for China’s IONOVA Life Science. Also, RenovoRx was the 84th company to go public in the US this year and ADC Therapeutics executed a $325m royalty deal.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.